Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.36 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19664525 | 1.00 | HDAC3 (0.41) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL9212520 | 0.94 | EPHX1 (0.47) | EPHX1CNR2ALDH1A1KCNN4KDM4E | |
| SCHEMBL24871094 | 0.84 | CNR2 (0.41) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL29131279 | 0.84 | CNR2 (0.41) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL10938696 | 0.83 | HDAC3 (0.46) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL19676420 | 0.83 | HDAC3 (0.35) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| (S)-Modafinil SCHEMBL1403524 | 0.82 | CYP2D6 (0.44) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Armodafinil SCHEMBL34489 | 0.82 | CYP2D6 (0.44) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Modafinil SCHEMBL3238686 | 0.82 | CYP2D6 (0.44) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Modafinil SCHEMBL34488 | 0.82 | CYP2D6 (0.44) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240342119-A1 | COMPOSITION FOR TREATING HYPERTROPHIC SCARS AND KELOIDS COMPRISING BENZHYDRYL THIOACETAMIDE COMPOUND AS ACTIVE INGREDIENT | CELLIONBIOMED INC. (KR) | 2024-10-17 | — | — | US | claimed |
| EP-4368177-A1 | COMPOSITION FOR TREATING HYPERTROPHIC SCARS AND KELOIDS COMPRISING BENZHYDRYL THIOACETAMIDE COMPOUND AS ACTIVE INGREDIENT | Cellionbiomed Inc. (KR) | 2024-05-15 | — | — | EP | claimed |
| WO-2023014003-A1 | COMPOSITION FOR TREATING HYPERTROPHIC SCARS AND KELOIDS COMPRISING BENZHYDRYL THIOACETAMIDE COMPOUND AS ACTIVE INGREDIENT | 셀라이온바이오메드 주식회사 | 2023-02-09 | — | — | WO | claimed |
| EP-3851099-A1 | COMPOSITION FOR TREATING FIBROTIC DISEASES, COMPRISING BENZHYDRYL THIOACETAMIDE COMPOUND AS ACTIVE INGREDIENT | Cellionbiomed Inc. (KR) | 2021-07-21 | — | — | EP | claimed |
| CN-113038942-A | Composition for treating fibrotic diseases containing benzhydrylthioacetamide (Benzhydryl ttoacetamide) compound as active ingredient | 细胞离子生物医学株式会社 | 2021-06-25 | — | — | CN | claimed |
| WO-1995001171-A1 | USE OF ACETAMIDE DERIVATIVES FOR MODIFYING FEEDING BEHAVIOUR | LABORATOIRE L. LAFON (FR) | 1995-01-12 | — | — | WO | claimed |
| EP-0097071-B1 | BENZHYDRYL SULFINYLACETAMIDE DERIVATIVES AND THEIR THERAPEUTICAL USE | LABORATOIRE L. LAFON Société anonyme dite: (FR) | 1985-08-28 | — | — | EP | claimed |
| EP-0097071-A1 | Benzhydryl sulfinylacetamide derivatives and their therapeutical use | LABORATOIRE L. LAFON Société anonyme dite: (FR) | 1983-12-28 | — | — | EP | claimed |
| US-12485088-B2 | Rapidly-orodispersible tablets having an interior cavity | Aprecia Pharmaceuticals LLC (US) | 2025-12-02 | — | — | US | disclosed |
| US-12324856-B2 | Oral drug dosage form comprising drug in the form of nanoparticles | Triastek, Inc. (CN) | 2025-06-10 | — | — | US | disclosed |
| CN-119735613-A | Crystalline forms of 5-chloro-N4- [2- (dimethylphosphoryl) phenyl ] -N2- { 2-methoxy-4- [4- (4-methylpiperazin-1-yl) piperidin-1-yl ] phenyl } pyrimidine-2, 4-diamine | 武田药品工业株式会社 | 2025-04-01 | — | — | CN | disclosed |
| US-20250085301-A1 | DATE RAPE DRUG DETECTION DEVICE AND METHOD OF USING SAME | EHRLICH ELAN (IL) | 2025-03-13 | — | — | US | disclosed |
| US-20250076321-A1 | DATE RAPE DRUG DETECTION DEVICE AND METHOD OF USING SAME | EHRLICH ELAN (IL) | 2025-03-06 | — | — | US | disclosed |
| US-20250076324-A1 | DATE RAPE DRUG DETECTION DEVICE AND METHOD OF USING SAME | EHRLICH ELAN (IL) | 2025-03-06 | — | — | US | disclosed |
| US-20130295196-A1 | LAUFLUMIDE AND THE ENANTIOMERS THEREOF, METHOD FOR PREPARING SAME AND THERAPEUTIC USES THEREOF | ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (FR) | 2013-11-07 | — | — | US | disclosed |
| WO-2012098235-A1 | LAUFLUMIDE AND THE ENANTIOMERS THEREOF, METHOD FOR PREPARING SAME AND THERAPEUTIC USES THEREOF | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (FR) | 2012-07-26 | — | — | WO | disclosed |
| WO-2012098235-A1 | LAUFLUMIDE AND THE ENANTIOMERS THEREOF, METHOD FOR PREPARING SAME AND THERAPEUTIC USES THEREOF | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (FR) | 2012-07-26 | — | — | WO | disclosed |
| WO-1995001171-A1 | USE OF ACETAMIDE DERIVATIVES FOR MODIFYING FEEDING BEHAVIOUR | LABORATOIRE L. LAFON (FR) | 1995-01-12 | — | — | WO | disclosed |
| EP-0097071-B1 | BENZHYDRYL SULFINYLACETAMIDE DERIVATIVES AND THEIR THERAPEUTICAL USE | LABORATOIRE L. LAFON Société anonyme dite: (FR) | 1985-08-28 | — | — | EP | disclosed |
| EP-0097071-A1 | Benzhydryl sulfinylacetamide derivatives and their therapeutical use | LABORATOIRE L. LAFON Société anonyme dite: (FR) | 1983-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12324856-B2 | Oral drug dosage form comprising drug in the form of nanoparticles | CYP2D6, CYP3A5, CYP3A7 | HDAC3 1315/4885HDAC4 1590/4885HDAC1 935/4885 |
| US-20130295196-A1 | LAUFLUMIDE AND THE ENANTIOMERS THEREOF, METHOD FOR PREPARING SAME AND THERAPEUTIC USES THEREOF | HCRTR2, HNMT, CYP2U1 | HDAC3 1015/4885HDAC4 648/4885HDAC1 987/4885 |
| US-20240342119-A1 | COMPOSITION FOR TREATING HYPERTROPHIC SCARS AND KELOIDS COMPRISING BENZHYDRYL THIOACETAMIDE COMPOUND AS ACTIVE INGREDIENT | TRPV5, COL2A1, FIBP | HDAC3 853/4885HDAC4 545/4885HDAC1 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.